Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Ofatumumab in Relapsed/Refractory CLL/SLL/PLL
NCT01217749Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Dec 2010
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), Richter's transformation (RT), sponsored by Pharmacyclics. Started Dec 2010; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)prolymphocytic leukemia (PLL)Richter's transformation (RT)
Beyond the preview
Go deeper on NCT01217749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217749.